The life sciences M&A landscape has undergone a dynamic evolution over the past decade, marked by periods of rapid growth and subsequent declines. The 2020 peak, driven by pandemic-fueled investments and strategic acquisitions, highlighted the industry’s responsiveness to global healthcare demands.
Following this peak, a declining trend in both the value and number of M&A deals is observed from 2021 onward. This report examines the key trends that shaped M&A activity in 2024, providing insights into the factors driving deal-making and the challenges reshaping investment strategies in the sector.
Read the Biotechgate Life Sciences M&A Report for more information and statistics on the M&A activity that took place in 2024 in the biotech, pharma and digital health sectors. Published biannually by Venture Valuation, the report is based on comprehensive data sourced from Biotechgate.